Close Menu

Pharmaceutical companies' interest in RNA interference is waning, says The New York Times' Andrew Pollack. Roche, Pfizer, and Abbott have all ceased to work on RNAi, though Roche's Klaus Stein says that he has "no doubt that at a certain point in time RNAi will make it to the market," but that there were "opportunities that have higher priorities" to focus on. Pollack adds that it is fairly common for a new technique to enjoy a moment of vogue before some interest in it is lost.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novamax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.